Full-Time

Relationship Analyst

Posted on 8/14/2025

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

Frankfurt, Germany

Hybrid

Hybrid role: 4 days on-site per week, with 1 day remote.

Category
Finance & Banking (1)
Requirements
  • 2-3 years of relevant client service experience, preferably gained within the Investment Management industry
  • Experience of working with institutional clients and consultants would be advantageous
  • Demonstrate a solid understanding of capital markets and/or investment products
  • Have a clear understanding of the KVG set up and work with these institutions throughout their career
  • Have a strong academic background, ideally including progress towards a professional qualification (e.g. CFA/CAIA or equivalent)
  • Demonstrate excellent verbal and written English language skills
  • Fluency in German is required; other languages would be advantageous
  • Be self-motivated, creative and enthusiastic
  • Be a natural collaborator who can work well in a small team
  • Strong interpersonal skills
Responsibilities
  • Command a thorough knowledge of the business, coupled with interpersonal skills to deal effectively with institutional clients and consultants; work closely with all members of the German/Austrian team, as well as many other functional areas of the firm, on a portfolio of assigned accounts in Frankfurt; conduct analysis of client portfolios, initiate investigations, respond to inquiries on a wide variety of topics, and perform other tasks as appropriate; coordinate prospect reporting, presentations, account maintenance, and ad hoc requests
  • Driving the preparation of high impact presentations of standard and/or customized client and prospect presentation materials, briefing books and collateral materials as well as meeting notes if in attendance and follow ups required for external meetings
  • Participating in client, consultant and prospect meetings and conference calls as appropriate
  • Conducting analysis, initiating investigations and responding to internal and external ad-hoc inquiries on a wide variety of topics, including portfolio and product specific information, investment guidelines, market trends, regulation considerations and fees
  • Acting as a point of contact for various groups within client organisations
  • Coordinating key client communications acting as a trusted liaison between clients and internal teams
  • Supporting the local Relationship and Business Development Managers in the organisation of client roadshows and client review meetings
  • Capturing and maintaining client data in relevant internal systems
  • Qualifying and coordinating Requests for Information (RFI’s) /Due Diligence Questionnaires (DDQ) and Requests for Proposals (RFP’s) and working with internal teams to ensure that each one receives the proper response
  • Developing an understanding of the depth and breadth of Wellington Management’s investment approaches and those products most relevant to the German channel
  • Champion data accuracy and insight-driven reporting leveraging the DMP (Delivery Management Platform) for client reporting, updating requirements on existing accounts and creating new templates during onboarding, working in partnership with our Investec team for SMA’s
  • Working with the CSO (Client Service Operations) team to provide responses on operational questions
Desired Qualifications
  • Progress towards professional qualification (e.g. CFA/CAIA or equivalent)
  • Additional language capabilities beyond German and English would be advantageous
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE